Because of advances in treatments for amyloidosis, in very specific circumstances clinicians have been able to make exceptions to the criteria that normally prevents amyloidosis patients from receiving hearts and have had excellent overall outcomes.
Encouragingly, new treatment options for cardiac amyloidosis have emerged recently and there is increasing awareness of this disease, once considered very rare.
A new era is upon us in the fields of cardio-oncology, amyloidosis and cardiac sarcoidosis. This is especially true of transthyretin amyloidosis with the recent advancements both in diagnosis and management.
Stanford Amyloid Center Hosts the Fall Meeting of the Northern California Amyloidosis Support Group Meeting
On October 20th the Northern California Amyloidosis Support Group celebrated it’s fourteenth year with a meeting held at Stanford’s Blake Wilbur Cancer Center.
Changes in the landscape of effective therapies for systemic light chain (AL) amyloidosis have led to substantial survival improvements at all stages of the disease, a study led by Dr. Witteles and the Stanford Amyloid Center.